Cove Street Capital LLC Sells 513,980 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Cove Street Capital LLC reduced its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCRFree Report) by 31.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,105,556 shares of the company’s stock after selling 513,980 shares during the period. Lifecore Biomedical makes up 2.8% of Cove Street Capital LLC’s portfolio, making the stock its 13th largest holding. Cove Street Capital LLC owned approximately 3.65% of Lifecore Biomedical worth $8,347,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in Lifecore Biomedical in the 2nd quarter valued at about $60,000. Barclays PLC purchased a new stake in Lifecore Biomedical in the 2nd quarter valued at about $87,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at about $101,000. Mirabella Financial Services LLP bought a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at about $149,000. Finally, Gabelli Funds LLC bought a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at about $161,000. 75.85% of the stock is owned by hedge funds and other institutional investors.

Lifecore Biomedical Trading Down 1.9 %

Shares of NASDAQ:LFCR traded down $0.16 during trading hours on Monday, hitting $8.39. The company’s stock had a trading volume of 123,588 shares, compared to its average volume of 155,412. Lifecore Biomedical, Inc. has a 52 week low of $1.52 and a 52 week high of $11.45. The firm’s fifty day moving average price is $6.67 and its 200 day moving average price is $7.55.

About Lifecore Biomedical

(Free Report)

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

See Also

Want to see what other hedge funds are holding LFCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lifecore Biomedical, Inc. (NASDAQ:LFCRFree Report).

Institutional Ownership by Quarter for Lifecore Biomedical (NASDAQ:LFCR)

Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.